Geographic Atrophy

This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.

Type 2 macular neovascularization, reductions in outer nuclear layer and central foveal thickness, and intraretinal fluid may indicate higher odds of retinal atrophy.

Recent data from the GALE trial align with OAKS and DERBY results, indicating a successful treatment of geographic atrophy.

Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.

Data released by Cognition Therapeutics shows that oral zervimesine resulted in substantially reduced lesion growth over 18 months compared to placebo.

The study indicates which biomarkers should be prioritized to predict neovascular AMD and geographic atrophy.

Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.

The February 2025 month in review covers 7 key pipeline updates in ophthalmology, including regulatory approvals, label expansions, and topline trial results.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

Our top 5 headlines include a target date for a cholesterol-lowering drug, long-term dermatology data, and an expanded dosing label for geographic atrophy.

The FDA approved an expanded label for avacincaptad pegol, removing limitations on the duration of dosing beyond 12 months.

The January 2025 ophthalmology month in review highlights the latest from the FDA, key updates to the ophthalmic pipeline, and the latest episode of New Insight.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

After accepting the avacincaptad pegol sNDA on January 6, 2025, the FDA has set a target action date for February 26.

A look back at some of our top coverage in ophthalmology from 2024, including pipeline news and FDA approvals.

FDA grants Rare Pediatric Disease, Fast Track designations to gildeuretinol, aiming to accelerate treatment for Stargardt disease.

The sNDA was intended to include positive two-year data in the US Prescribing Information for avacincaptad pegol based on the GATHER2 clinical trial.

Decreasing Vitamin A dimerization could be a potential mechanism to treat geographic atrophy, according to results from the two-year SAGA study at AAO 2024.

Pegcetacoplan injection showed increased benefit for subfoveal GA, with as few as 6 injections, over 3 years in the GALE extension trial.

In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.

Gildeuretinol showed a clinically meaningful reduction in geographic atrophy lesion growth and a favorable safety profile at 24 months in the Phase 3 SAGA trial.

This August 2024 month in review highlights updates to the ophthalmic pipeline, metformin for geographic atrophy, and decreasing rates of postoperative endophthalmitis in the US.

A new treatment era was born with first-time geographic atrophy approvals in 2023, but many are still searching for the next addition to the treatment landscape.

Our July 2024 month in review in ophthalmology includes the latest updates to the ophthalmological pipeline and a trio of studies on the treatment landscape for retinal diseases.

Geographic atrophy in eyes with dry AMD and macular atrophy in fellow eyes with neovascular AMD demonstrate similar growth rates.